Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

A non-invasive form of treatment for clinical depression is hoping to provide even faster results thanks to new research.

The synergistic relationship between psychiatric medications and psychotherapy is often overlooked. By managing discreet ...

The US Food and Drug Administration (FDA) has expanded the approval for Johnson & Johnson’s nasal spray Spravato to allow its standalone use in patients with depression, the company said on Jan 21.

The U.S. Food and Drug Administration on Tuesday approved the first nasal spray that will help with treating major depressive ...

A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...